Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Average Recommendation of “Hold” by Analysts

Sensus Healthcare, Inc. (NASDAQ:SRTS) has earned a consensus rating of “Hold” from the five brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $8.00.

Several equities analysts have recently issued reports on the company. Zacks Research upgraded Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 22nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Sensus Healthcare from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th.

Sensus Healthcare Trading Up 7.4%

Shares of NASDAQ:SRTS opened at $4.76 on Friday. The firm has a 50 day moving average of $4.00 and a 200-day moving average of $3.88. Sensus Healthcare has a 12 month low of $3.03 and a 12 month high of $9.08. The stock has a market capitalization of $78.16 million, a PE ratio of -25.05 and a beta of 1.21.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.06. Sensus Healthcare had a negative net margin of 8.44% and a negative return on equity of 5.67%. The business had revenue of $6.88 million for the quarter, compared to analysts’ expectations of $6.31 million. On average, research analysts predict that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Joseph C. Sardano acquired 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was acquired at an average price of $4.03 per share, with a total value of $100,750.00. Following the purchase, the chief executive officer directly owned 1,200,293 shares in the company, valued at approximately $4,837,180.79. This trade represents a 2.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Eric Sachetta bought 7,000 shares of the business’s stock in a transaction on Friday, November 21st. The stock was bought at an average price of $3.93 per share, for a total transaction of $27,510.00. Following the transaction, the director directly owned 140,113 shares of the company’s stock, valued at approximately $550,644.09. This represents a 5.26% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have purchased 36,500 shares of company stock valued at $147,570. 8.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sensus Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of SRTS. Acadian Asset Management LLC increased its holdings in Sensus Healthcare by 35.3% in the 1st quarter. Acadian Asset Management LLC now owns 470,713 shares of the company’s stock worth $2,225,000 after purchasing an additional 122,746 shares in the last quarter. Kingstone Capital Partners Texas LLC acquired a new position in shares of Sensus Healthcare in the second quarter valued at approximately $3,170,000. Chapin Davis Inc. raised its holdings in Sensus Healthcare by 66.7% in the 2nd quarter. Chapin Davis Inc. now owns 25,000 shares of the company’s stock valued at $118,000 after buying an additional 10,000 shares during the last quarter. Sachetta LLC boosted its position in Sensus Healthcare by 3.0% during the 2nd quarter. Sachetta LLC now owns 128,675 shares of the company’s stock worth $610,000 after buying an additional 3,788 shares during the period. Finally, Evernest Financial Advisors LLC bought a new stake in Sensus Healthcare during the 2nd quarter worth approximately $255,000. Institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.